Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3

Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3

Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early breast cancer (BC), potentially setting the scene for more effective implementation of checkpoint-targeted immunotherapy. This issue has been investigated in the current study in which alterations in the plasma conc...

Full description

Bibliographic Details
Main Authors: Bernardo L. Rapoport, Helen C. Steel, Carol A. Benn, Simon Nayler, Teresa Smit, Liezl Heyman, Annette J. Theron, Nomsa Hlatshwayo, Luyanda L.I. Kwofie, Pieter W.A. Meyer, Ronald Anderson
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
breast cancer
co-inhibitory checkpoints
co-stimulatory checkpoints
cytotoxic T cells
immunotherapy
immune dysregulation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1097309/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1097309/full

Similar Items